Towards an effective HIV vaccine by Rogier Sanders and Godelieve de Bree (Amsterdam UMC)
There is not yet a vaccine against the second deadliest infection in the world after tuberculosis: HIV. Rogier Sanders and Godelieve de Bree of the Amsterdam UMC are optimistic about the possibility of developing one now. It’s for the first time that a vaccine is being developed in one hospital (Amsterdam UMC) from the design phase to the safety and efficacy studies in healthy volunteers. It’s also unique that these studies for an HIV vaccine are being done in the Netherlands.
However, actually making the vaccine for testing in humans is very expensive. Rogier and Godelieve are trying to make that happen and are now looking for funding. The potential impact on treating HIV through this vaccine is enormous!
Explore other Stories:
Developing a product of clinical value takes time
With their user-friendly measurement instrument for the quantification of spasticity, Jules Becher and Jaap Harlaar aim to revolutionise therapy in children with spasticity. Becher explains that the cause of spastic muscles can be of neurophysiological or biomechanical origin, each requiring specific therapy. By employing three different sensors the new device can pinpoint the precise cause […]
Putting your research results to work in clinical practice
Cancer Center Amsterdam has a dedicated IXA alliance office to assist oncology researchers in creating value from their expertise and discoveries
Five years of Demonstrator Lab
At Demonstrator Lab, two locations: @Zuidas and @Science Park, researchers and students from the HvA, UvA, VU and Amsterdam UMC can go to develop and test their research-based idea for a product or service. In the past five years, more than 100 projects were launched, from which 21 start-ups have emerged. Jardo Stammeshaus (co-founder of […]